Compare REF & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REF | OBX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.5M | 861.1M |
| IPO Year | 2026 | 2026 |
| Metric | REF | OBX |
|---|---|---|
| Price | $18.41 | $10.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $19.25 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 388.9K | 344.9K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.39 | N/A |
| Revenue Next Year | $16.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.85 | $11.52 |
| 52 Week High | $17.26 | $39.00 |
| Indicator | REF | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 42.05 |
| Support Level | $12.55 | $11.84 |
| Resistance Level | N/A | $19.97 |
| Average True Range (ATR) | 0.99 | 1.24 |
| MACD | 0.22 | 0.29 |
| Stochastic Oscillator | 96.91 | 39.31 |
Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.